Cargando…

Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells

BACKGROUND: Patients with triple negative breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumour relapse, due to the resistance to chemotherapy. These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs). Therefore, targeting BCSCs is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Jun, Raffa, Fatmah Al, Dai, Meiou, Moamer, Alaa, Khadang, Baharak, Hachim, Ibrahim Y., Bakdounes, Khldoun, Ali, Suhad, Jean-Claude, Bertrand, Lebrun, Jean-Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288167/ https://www.ncbi.nlm.nih.gov/pubmed/30482914 http://dx.doi.org/10.1038/s41416-018-0287-3

Ejemplares similares

Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition
por: Tian, Jun, et al.
Publicado: (2021)

Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer
por: Tian, Jun, et al.
Publicado: (2017)

TGFβ/cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity
por: Yan, Gang, et al.
Publicado: (2021)

A role for kinesin-1 subunits KIF5B/KLC1 in regulating epithelial mesenchymal plasticity in breast tumorigenesis
por: Moamer, Alaa, et al.
Publicado: (2019)

Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis
por: Shams, Anwar, et al.
Publicado: (2021)

Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy
por: López-Ozuna, Vanessa M., et al.
Publicado: (2016)

Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance
por: Yan, Gang, et al.
Publicado: (2023)

CPSF6 is a Clinically Relevant Breast Cancer Vulnerability Target: Role of CPSF6 in Breast Cancer
por: Binothman, Najat, et al.
Publicado: (2017)

CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
por: Dai, Meiou, et al.
Publicado: (2016)

Concomitant Expression of Prolactin Receptor and TGFβ Receptors in Breast Cancer: Association with Less Aggressive Phenotype and Favorable Patient Outcome
por: Hachim, Ibrahim Y., et al.
Publicado: (2019)

A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion
por: Dai, Meiou, et al.
Publicado: (2012)

Erratum to: A novel function for p21 Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion
por: Dai, Meiou, et al.
Publicado: (2017)

Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration
por: Hachim, Ibrahim Y., et al.
Publicado: (2017)

Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes
por: Guo, Jimin, et al.
Publicado: (2014)

Author Correction: Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration
por: Hachim, Ibrahim Y., et al.
Publicado: (2022)

Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
por: Bahman, Fatemah, et al.
Publicado: (2021)

Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion
por: Dai, Meiou, et al.
Publicado: (2013)

Erratum to: Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion
por: Dai, Meiou, et al.
Publicado: (2017)

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
por: Gaule, Patricia, et al.
Publicado: (2019)

In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
por: Dai, Meiou, et al.
Publicado: (2021)

Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer
por: Ali, Suhad, et al.
Publicado: (2022)

In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
por: Passos, Ioannis D, et al.
Publicado: (2023)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Ovarian Mixed Malignant Brenner-Mucinous Tumor with Signet Ring Cells
por: Khadang, Baharak, et al.
Publicado: (2020)

Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer
por: Zeng, Fan, et al.
Publicado: (2015)

Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
por: McKnight, Brooke N., et al.
Publicado: (2020)

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

In Silico Analysis of Publicly Available Transcriptomic Data for the Identification of Triple-Negative Breast Cancer-Specific Biomarkers
por: Kaddoura, Rachid, et al.
Publicado: (2023)

Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents
por: Bajor, Malgorzata, et al.
Publicado: (2018)

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)
por: Qian, Xiao-Long, et al.
Publicado: (2017)

Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy
por: Niza, Enrique, et al.
Publicado: (2019)

Barium Titanate Nanoparticles Sensitise Treatment-Resistant Breast Cancer Cells to the Antitumor Action of Tumour-Treating Fields
por: Yoon, Yi Na, et al.
Publicado: (2020)

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy
por: McLaughlin, Ronan P., et al.
Publicado: (2019)

The Roles of DNA Demethylases in Triple-Negative Breast Cancer
por: Panjarian, Shoghag, et al.
Publicado: (2021)

Sensitisation of cancer cells to radiotherapy by serine and glycine starvation
por: Falcone, Mattia, et al.
Publicado: (2022)

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
por: Niza, Enrique, et al.
Publicado: (2019)

Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model
por: Song, Ningning, et al.
Publicado: (2018)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2iee6mc36rcinrbr7em6fbavv5